Bariki Mtafya HoD: Laboratory Sciences

{tab title="Qualifications" class="solid"}

• PhD scholar in Biomedical Science, University of St. Andrews, UK (2016-2019)
• MSc. Infection and Immunity, University College London (UCL), UK (2012-2013)
• BSc. Molecular Biol & Biotech, University of Dar es Salaam, Tanzania (2006-2009)

{tab title="Interests" class="green"}

• Research interest: Infectious diseases particularly tuberculosis/co-infection with HIV, host-pathogen interaction and antimicrobial resistance
• Research experience: 10 years

{tab title="Grants" class="blue"}

• A 3-year Commonwealth PhD studentship at University of St. Andrews to investigate the performance, implementability and benefit of a novel molecular bacterial load assay for routine monitoring of tuberculosis treatment and detection of viable and lipid rich mycobacteria

{tab title="Publications" class="blue"}

1. Andrea Rachow, Elmar Saathoff, Bariki Mtafya, Daniel Mapamba, Chacha Mangu, Gabriel Rojas-Ponce, Nyanda E. Ntinginya, Martin Boeree, Norbert Heinrich, Stephen H. Gillespie, Michael Hoelscher.The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay. Tuberculosis Volume 110, Pages 56-58 (May 2018) DOI: 10.1016/j.tube.2018.04.001
2. Jason M. Bacha, Katherine Ngo, Petra Clowes, Heather R. Draper, Elias N. Ntinginya, Andrew DiNardo, Chacha Mangu, Issa Sabi, Bariki Mtafya and Anna M. Mandalakas. Why being an expert – despite xpert –remains crucial for children in high TB burden settings; BMC Infectious Diseases (2017) 17:123 DOI 10.1186/s12879-017-2236-9
3. Martin J Boeree*, Norbert Heinrich*, Rob Aarnoutse, Andreas H Diacon, Rodney Dawson, Sunita Rehal, Gibson S Kibiki, Gavin Churchyard, Ian Sanne, Nyanda E Ntinginya, Lilian T Minja, Robert D Hunt, Salome Charalambous, Madeleine Hanekom, Hadija H Semvua, Stellah G Mpagama, Christina Manyama, Bariki Mtafya, Klaus Reither, Robert S Wallis, Amour Venter, Kim Narunsky, Anka Mekota, Sonja Henne, Angela Colbers, Georgette Plemper van Balen, Stephen H Gillespie, Patrick P J Phillips, Michael Hoelscher, on behalf of the PanACEA consortium† ; High-dose rifampicin, moxifl oxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 2017; 17: 39–49
4. Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, Farmer EC, Khonga M, Evangelopoulos D, Honeyborne I, Rachow A, Heinrich N, Ntinginya NE, Bhatt N, Davies GR, Jani IV, McHugh TD, Kibiki G, Hoelscher M, Gillespie SH. Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings. The International Journal of Tuberculosis and Lung Disease. 2016 Aug 1; 20(8):1004-9.
5. Jonny G Peter*, Lynn S Zijenah*, Duncan Chanda*, Petra Clowes*, Maia Lesosky, Phindile Gina, Nirja Mehta, Greg Calligaro, Carl J Lombard, Gerard Kadzirange, Tsitsi Bandason, Abidan Chansa, Namakando Liusha, Chacha Mangu, Bariki Mtafya, Henry Msila, Andrea Rachow, Michael Hoelscher, Peter Mwaba, Grant Theron, Keertan Dheda. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicounty, open-label, randomised controlled trial. Lancet 2016; 387: 1187–97
6. Inge Kroidl, Petra Clowes, Klaus Reither, Bariki Mtafya, Gabriel Rojas-Ponce, Elias N. Ntinginya, Mariam Kalomo, Lilian T. Minja, Dickens Kowuor, Elmar Saathoff, Arne Kroidl, Norbert Heinrich, Leonard Maboko, Matthew Bates, Justin O'Grady, Alimuddin Zumla, Michael Hoelscher, Andrea Rachow. Performance of urine Lipoarabinomannan assays for pediatric tuberculosis in Tanzania. Eur Respir J.2015 Jun 25. pii: ERJ-00033-2015. doi: 10.1183/09031936.00003315.
7. Bowness, R., Boeree, M. J., Aarnoutse, R., Dawson, R., Diacon, A., Mangu, C., Heinrich N., Ntinginya NE., Kohlenberg A., Mtafya, B., Phillips P.J., Rachow A., Plember van Balen G and Gillespie S.H (2014). The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. Journal of Antimicrobial Chemotherapy, dku415
8. Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD and Heinrich N on behalf of the Pan African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA). The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment; Journal of clinical microbiology. 2014; 52(8):3064-7
9. E.N. Ntinginya, S.B. Squire, K.A. Millington, B. Mtafya, E. Saathoff, N. Heinrich, G. Rojas-Ponce, D. Kowuor, L. Maboko, P. Clowes, M. Hoelscher, A. Rachow. Performance of Xpert MTB/RIF assay in an active case finding strategy-a pilot study from Tanzania. Int J Tuberc Lung Dis. 2012 Nov; 16(11):1468-70.
10. Andrea Rachow, Petra Clowes, Elmar Saathoff, Bariki Mtafya, Epiphania Michael, Elias N. Ntinginya, Dickens Kowour, Gabriel Rojas-Ponce, Arne Kroidl, Leonard Maboko, Norbert Heinrich, Klaus Reither, Michael Hoelscher. Increased and expedited case detection by Xpert MTB/RIF assay in childhood TB: a prospective cohort study. Clin Infect Dis. 2012 May; 54(10):1388-96.
11. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, Ntinginya EN,O'Grady J, Huggett J, Dheda K, Boehme C,Perkins M, Saathoff E, Hoelscher M. Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay; A Clinical Validation Study. PLoS One. 2011; 6(6): e20458.

{tab title="Current Projects" class="green"}

• TB Sequel
• Simplici TB
• POR TB trial
• AFRICOS
• PanaCEA II (Biomarkers and Microbiology core)
• New TB diagnostics in children
  • RaPaed
  • Stool quantitative PCR (qPCR)

{tab title="Contacts" class="solid"}

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

{/tabs}